Navigation Links
Campbell Alliance Clinical Development Practice to Conduct Two Workshops at 44th DIA Annual Meeting

RALEIGH, N.C., June 17 /PRNewswire/ -- Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced that its Clinical Development Practice will conduct two workshops at the 44th Drug Information Association (DIA) Annual Meeting to be held June 22 to 26, 2008, at the Boston Convention and Exhibition Center.

Tim Dietlin, Vice President, will lead a workshop that examines best practices for accelerated study start-up, and Gary Tyson, Senior Vice President, will conduct a workshop that will explore strategies for becoming the sponsor of choice for clinical investigators. In addition to the Campbell Alliance executives leading these sessions, three industry executives will serve on the panel at each of the two workshops.

Mr. Dietlin's workshop, titled "The Keys to Establishing Best Practices for Accelerated Study Start-Up," will be conducted on Monday, June 23 from 3:30 pm to 5:00 pm. The workshop, which is part of the Clinical Research and Development track, will examine best practices and methods for developing a study start-up framework, such as conducting an upfront assessment of an organization's current environment and approaches to study start-up, evaluating the steps that can be taken to streamline operations, and developing training requirements and materials to integrate the framework into daily start-up activities.

"The speed of clinical study start-up can affect an entire clinical trial, and the study team has only one shot at getting it right," Mr. Dietlin said. "Overall success or failure is typically determined well before start-up, so proper planning and management is critical, especially given the ever-increasing complexity of managing the range of activities involved in start-up including technology requirements, site requirements, and general study management."

Mr. Dietlin brings extensive management consulting experience to Campbell Alliance as a Vice President in the Clinical Development practice. He specializes in helping clients improve their clinical development operations and business processes to optimize the flow of critical information, increase the efficacy of key processes, and enhance organizational capabilities. Mr. Dietlin earned his MBA from DePaul University's Kellstadt Graduate School of Business and has a BA from Loyola University of Chicago.

On the day after Mr. Dietlin's workshop, Tuesday, June 24, Mr. Tyson will conduct a workshop titled "Becoming a Sponsor of Choice for Clinical Investigators" from 8:00 am to 9:30 am. The workshop, which is part of the Clinical Trial Management/Clinical Supplies track, will discuss key factors driving investigators' choices of clinical study sponsors. It will also explore tactics for identifying a pharmaceutical or biotech company's strengths and weaknesses with respect to conducting clinical trials, as well as examine strategies for improving a company's relationship with the study sites and investigators it values most.

"It's critical that a pharmaceutical company do everything it can to be the study sponsor that sites prefer to work with -- the sponsor of choice -- because there are so many clinical trials that are competing for the same patients," Mr. Tyson said. "Companies will gain a clear advantage if they understand what's behind an investigator's or study site's decision to work with a particular sponsor," he said.

As the head of Campbell Alliance's Clinical Development Practice, Mr. Tyson leads a team that provides a range of operational improvement services to clinical development organizations within pharmaceutical and biotech companies, as well as at leading contract research organizations (CROs). He is a veteran of numerous electronic-data-capture-related initiatives, and brings a wealth of knowledge and experience in process improvement, organizational design, and clinical development to his consulting engagements.

The DIA's Annual Meeting brings together thousands of delegates from pharmaceutical and biotech organizations around the world. With 26 content-area tracks, more than 1,000 speakers, and nearly 350 sessions, the presentations are geared to attendees of all experience and functional levels. The DIA Annual Meeting offers valuable professional cross-functional learning, continuing education credits, and networking experiences. For more information, please visit:

Executives from Campbell Alliance speak at many conferences in the US and Europe each year. For a full listing of events, please refer to the company's online conference calendar at

About the Clinical Development Practice at Campbell Alliance

Campbell Alliance's Clinical Development practice includes operations improvement specialists with expertise in clinical development. The practice specializes in helping clients correct or improve the processes that are most often responsible for delays and budget overruns in clinical development.

Services include

-- Development of outsourcing strategies

-- Process improvement for data collection and management, patient

recruitment, and project management

-- Organizational development and improvement

-- Electronic data capture consulting and implementation support

-- Clinical trial analytics

About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include most of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Managed Markets, Sales, and Trade and Distribution. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and London, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit


James Forte

Director, Public and Media Relations

Campbell Alliance

919-844-7100, extension 7195

SOURCE Campbell Alliance
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
2. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
3. Campbell Alliance Named Best Place to Work by Triangle Business Journal
4. Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver
5. Campbell Alliance Launches New Practice Area Focused on Trade and Distribution
6. Campbell Alliance Trade and Distribution Practice to Chair CBI 3rd Annual Fee for Service and EDI Data Management Conference
7. Campbell Alliance Brand Management Practice to Discuss Managing Launch Logistics at the EyeForPharma Oncology Summit
8. Campbell Alliance Brand Management and Managed Markets Practices to Speak at CBIs Early Commercialization Conference
9. Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference
10. Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies
11. Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group
Post Your Comments:
(Date:10/12/2015)... SAN FRANCISCO , October 12, 2015 ... reach USD 6.49 billion by 2022, according to a new ... can be attributed to rise in incidence of oncology diseases ... detection market is expected to reach USD 6.49 billion ... Research, Inc. This growth in demand can be attributed to ...
(Date:10/12/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... commercializing novel treatments in oncology, endocrinology and women,s health, ... the Company,s former Senior Vice President, Chief Financial Officer, ... City office.  David A. ... the Company commented, "After a comprehensive review, the Company,s ...
(Date:10/12/2015)... , October 12, 2015 ... Dario™ Diabetes Management Solution, today announced its Medical Director, ... case study at MobiHealth,s 5th EAI International Conference ... "Transforming healthcare through innovations in mobile and wireless technologies," ... England from October 14 - 16, 2015. ...
(Date:10/12/2015)... Belgium , Oct. 12, 2015 VolitionRx ... from a completed clinical study of its NuQ ® ... in the online issue of Clinical Epigenetics , the ... was conducted in collaboration with Lund ... Roland Andersson , MD, PhD, Professor of Surgery and Vice-Dean, ...
Breaking Biology Technology:
(Date:10/8/2015)... , October 8, 2015 ... or the "Company"), a biometric authentication company focused ... of the Wocket® smart wallet announces that revenues ... were approximately $410,000 compared with $113,00 for the ... the 9 months ended September 30, 2015 were ...
(Date:10/7/2015)... -- NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet ... term executive at American Express has been appointed to ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... the Wocket® smart wallet announces Mr. Stanley E. ...
(Date:10/6/2015)... Oct. 6, 2015  Maverix Biomics, Inc., a ... to its software portfolio with the debut of ... differential expression in eukaryotes. The software is integrated ... cloud-based genomic analysis solution that leverages proven open-source ... next-generation sequencing efforts. Garry Nolan,s ...
Breaking Biology News(10 mins):